# (Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma

> **NCT05907954** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **IDEAYA Biosciences** · enrollment: 160 (estimated)

## Conditions studied

- Uveal Melanoma

## Interventions

- **DRUG:** Darovasertib

## Key facts

- **NCT ID:** NCT05907954
- **Lead sponsor:** IDEAYA Biosciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-07-03
- **Primary completion:** 2027-04-30
- **Final completion:** 2030-04-30
- **Target enrollment:** 160 (ESTIMATED)
- **Last updated:** 2026-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05907954

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05907954, "(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05907954. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*